Selective targeting of gain-of-function KCNQ1 mutations predisposing to atrial fibrillation

Circ Arrhythm Electrophysiol. 2013 Oct;6(5):960-6. doi: 10.1161/CIRCEP.113.000439. Epub 2013 Sep 4.

Abstract

Background: Atrial fibrillation is the most common sustained cardiac arrhythmia in adults. We hypothesized that gain-of-function KCNQ1 mutations previously associated with familial atrial fibrillation have distinct pharmacological properties that may enable targeted inhibition.

Methods and results: Wild-type (WT) KCNQ1 or the familial atrial fibrillation mutation KCNQ1-S140G was heterologously coexpressed with KCNE1 to enable electrophysiological recording of the slow delayed rectifier current (IKs) and investigation of pharmacological effects of the IKs selective blocker HMR-1556. Coexpression of KCNQ1-S140G with KCNE1 generated potassium currents (S140G-IKs) that exhibited greater sensitivity to HMR-1556 than WT-IKs. Enhanced HMR-1556 sensitivity was also observed for another gain-of-function atrial fibrillation mutation, KCNQ1-V141M. Heteromeric expression of KCNE1 with both KCNQ1-WT and KCNQ1-S140G generated currents (HET-IKs) with gain-of-function features, including larger amplitude, a constitutively active component, hyperpolarized voltage dependence of activation, and extremely slow deactivation. A low concentration of HMR-1556, which had little effect on WT-IKs but was capable of inhibiting the mutant channel, reduced both instantaneous and steady state HET-IKs to levels that were not significantly different from WT-IKs and attenuated use-dependent accumulation of the current. In cultured adult rabbit left atrial myocytes, expression of S140G-IKs shortened action potential duration compared with WT-IKs. Application of HMR-1556 mitigated S140G-IKs-induced action potential duration shortening and did not alter action potential duration in cells expressing WT-IKs.

Conclusions: The enhanced sensitivity of KCNQ1 gain-of-function mutations for HMR-1556 suggests the possibility of selective therapeutic targeting, and, therefore, our data illustrate a potential proof of principle for genotype-specific treatment of this heritable arrhythmia.

Keywords: antiarrhythmic drugs; arrhythmias, cardiac; atrial fibrillation; genetics; potassium channels.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Atrial Fibrillation / genetics*
  • Cells, Cultured
  • Chromans / pharmacology
  • Cricetulus
  • Genetic Predisposition to Disease
  • KCNQ1 Potassium Channel / genetics*
  • Mutation*
  • Myocytes, Cardiac
  • Patch-Clamp Techniques
  • Plasmids
  • Potassium Channels, Voltage-Gated / genetics*
  • Rabbits
  • Risk Factors
  • Sulfonamides / pharmacology

Substances

  • Chromans
  • HMR 1556
  • KCNQ1 Potassium Channel
  • Potassium Channels, Voltage-Gated
  • Sulfonamides